WebMD

Your Guide to Ocrevus and Ocrevus Zunovo for Multiple Sclerosis (MS)

How Does Ocrevus or Ocrevus Zunovo Work in MS? MS happens when your immune system damages the protective covering around the nerves in your brain, called myelin. This affects how your brain ...
Business Wire

First-Ever Clinical Trial Exclusively in Black and Hispanic / Latinx People Living With Multiple Sclerosis Shows Genentech’s Ocrevus Effectively Manages Disease Activity

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced results from the Phase IV CHIMES (CHaracterization of ocrelizumab In ...
Business Wire

Genentech’s Subcutaneous Ocrevus One-Year Data Demonstrates Near-Complete Suppression of Clinical Relapses and Brain Lesions in Patients With Progressive and Relapsing Forms ...

– Results from the Phase III study showed that subcutaneous (SC) injection was consistent with IV infusion and demonstrated near-complete suppression of relapse activity (97%) and MRI lesions (97.2%) ...
FiercePharma

Roche doubles down with another subcutaneous FDA nod, this one for MS star Ocrevus

When Roche's Genentech gained approval for Ocrevus in 2017, the first-in-class infused drug quickly became the best-selling treatment in a crowded multiple sclerosis (MS) market. Three years later, ...
Nasdaq

FDA Approves Ocrevus Zunovo™ as the First and Only Twice-a-Year 10-Minute Subcutaneous Injection for People With Relapsing and Progressive Multiple Sclerosis

– Ocrevus Zunovo™ has the potential to expand treatment options to centers without IV infrastructure or with IV constraints, like at a doctor's office – – This approval is backed by a decade of proven ...
Seeking Alpha

Roche's Ocrevus' 10-year data shows MS drug cuts disability progression

Roche's (OTCQX:RHHBY) (OTCQX:RHHBF) (OTCPK:RHHVF) multiple sclerosis (MS) drug Ocrevus showed that after 10 years of treatment 77% of patients with relapsing MS were free from disability progression ...